Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Agreement for depression diagnosis between DSM-IV-TR criteria, three validated scales, oncologist assessment, and psychiatric clinical interview in elderly patients with advanced ovarian cancer.
Rhondali W, Freyer G, Adam V, Filbet M, Derzelle M, Abgrall-Barbry G, Bourcelot S, Machavoine JL, Chomat-Neyraud M, Gisserot O, Largillier R, Le Rol A, Priou F, Saltel P, Falandry C. Rhondali W, et al. Among authors: gisserot o. Clin Interv Aging. 2015 Jul 13;10:1155-62. doi: 10.2147/CIA.S71690. eCollection 2015. Clin Interv Aging. 2015. PMID: 26203235 Free PMC article.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
[A gamma, from alpha to omega...].
Gisserot O, Crémades S, Landais C, Bernard P, de Jaureguiberry JP. Gisserot O, et al. Rev Med Interne. 2004 Jun;25 Suppl 2:S224-6. doi: 10.1016/s0248-8663(04)80010-9. Rev Med Interne. 2004. PMID: 15460457 French. No abstract available.
[Eosinophils that take over the head!... ].
Gisserot O, Crémades S, Bernard P, El Baaj M, Libert N, de Jauréguiberry JP. Gisserot O, et al. Rev Med Interne. 2005 Jul;26 Suppl 2:S256-7. doi: 10.1016/s0248-8663(05)81274-3. Rev Med Interne. 2005. PMID: 16129164 French. No abstract available.
[Prostatic actinomycosis in a diabetic patient].
Chemsi M, Gisserot O, Cremades S, Bernard P, de Jauréguiberry JP. Chemsi M, et al. Among authors: gisserot o. Rev Med Interne. 2007 Jun;28(6):424-5. doi: 10.1016/j.revmed.2007.01.018. Epub 2007 Feb 8. Rev Med Interne. 2007. PMID: 17320248 French.
74 results